## RECEIVED CENTRAL FAX CENTER

ISIS PATENT DEPT

JAN 2 4 2007 PTO/SB/21 (09-06) Approved for use through 03/31/2007. OMB 0851-0031 U.S. Patent and Tredemark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1985, no persons are required to respond to lection of information unless it displays a valid OMB control number. Application Number 09/891.793 TRANSMITTAL Filing Date 08/26/2001 **FORM** First Named Inventor David J. Ecker Art Unit Examiner Name Jeffrey N. Fredman (to be used for all correspondence after initial filling) Attorney Docket Number Total Number of Pages in This Submission DIBIS-0003US **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Fee Attached Licensing-related Papers of Appeals and Interferences 0 Appeal Communication to TC Pelition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petilion to Convert to a After Final Provisional Application Proprietary Information Power of Attorney, Revocation Affidavits/declaration(s) Change of Correspondence Address Status Letter Other Enclosure(s) (please Identify Extension of Time Request Terminal Disclaimer below): Request for Refund Express Abandonment Request Information Disclosure Statement CD, Number of CD(s) Landscape Table on CD Certified Copy of Priority Remarks Document(s) Amendment in response to Notice of Drawing Inconsistency with Specification mailed Reply to Missing Parts/ 01/08/2007 Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Isis Pharmaceuticals, Inc. Signature Printed name Jeffrey Landes, Esq. Date 24. 2007 Reg. No. 55,355 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mall in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office. U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Jamie Toupal

Typed or printed name

## RECEIVED CENTRAL FAX CENTER JAN 2 4 2007

DOCKET NO .: DIBIS-0003US Application No.: 09/891,793

Office Action Dated: January 8, 2007

PATENT

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

ECKER, David J. et al.

Confirmation No.: 1490

Application No.: 09/891,793

Group Art Unit: 1637

Filing Date: June 26, 2001

Examiner: FREDMAN, Jeffrey N.

METHODS FOR PROVIDING BACTERIAL BIOAGENT

CHARACTERIZING INFORMATION

#### Certificate of Facsimile Transmission

I hereby certify that this paper is being facsimile transmitted or is being deposited yig to the address shown below on

Med Stop Issue Fee

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

### RESPONSE TO NOTICE OF DRAWING INCONSISTENCY WITH SPECIFICATION

#### Commissioner:

In response to the Official Action dated January 8, 2007, and having a date for response set to expire on February 8, 2007, reconsideration is respectfully requested in view of the amendments and/or remarks as indicated below:

- Amendments to the Specification begin on page 2 of this paper.  $\boxtimes$
- 冈 Remarks/Arguments begin on page 5 of this paper.